STD Surveillance Network (SSuN), 36389-36394 [05-12410]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 70, Number 120 (Thursday, June 23, 2005)]
[Notices]
[Pages 36389-36394]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12410]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


STD Surveillance Network (SSuN)

    Announcement Type: New.
    Funding Opportunity Number: AA055.
    Catalog of Federal Domestic Assistance Number: 93.977.
    Key Dates:
    Letter of Intent Deadline: July 8, 2005.
    Application Deadline: July 25, 2005.

I. Funding Opportunity Description

    Authority: Sections 317(k)(2) and 318 of the Public Health Service 
Act [42 U.S.C. Sections 247b(k)(2) and 247c], as amended.
    Background: A dynamic STD surveillance network, comprised of local 
enhanced STD surveillance systems following common protocols, has the 
potential to fill several important gaps in the existing national STD 
surveillance system. National STD surveillance data, reported through 
the National Electronic Telecommunication Surveillance System (NETSS), 
currently involves a limited number of demographic data elements 
collected from all states for a limited number of sexually transmitted 
diseases (chancroid, chlamydia, gonorrhea, and syphilis). Weekly 
reporting through NETSS is insufficient for rapid identification of 
many trends in disease, and does not support the collection and 
reporting of data on many relevant STD risk behaviors. Furthermore, 
even if trends in disease or risk behaviors are identified, the 
national STD morbidity surveillance infrastructure comprised of NETSS 
reporting from all states has limited capacity to be easily and rapidly 
modified. Even though the transition to the National Electronic Disease 
Surveillance System (NEDSS) is intended to improve the timeliness and 
flexibility of national STD surveillance, the flexibility of national 
morbidity reporting will always be restricted by the scale of the 
system.
    CDC has traditionally relied on supplemental activities such as 
prevalence monitoring projects and special studies to enhance STD 
surveillance at a national level. While these types of activities focus 
on

[[Page 36390]]

specific at-risk sub-populations, an STD surveillance network would 
focus activities on the larger population with disease. The STD 
surveillance network would also have the ability to monitor what is 
happening across the range of STD entities (gonorrhea, herpes, 
chlamydia, syphilis, HPV, etc.). In addition, it should provide the 
infrastructure and potential to detect emerging issues and 
environmental changes (ex: increases in lymphogranuloma venereum (LGV), 
resistant gonorrhea, resistant syphilis, HPV, illicit drug use). An 
initial focus and priority would be to obtain enhanced data on 
gonorrhea. Additional priority areas would be determined by the STD 
surveillance network on an ongoing basis.
    Purpose: The purposes of the program are to: develop a dynamic STD 
surveillance network comprised of local enhanced STD surveillance 
systems, following common protocols, to improve the capacity of 
national, state, and local STD programs to detect, monitor, and respond 
rapidly, flexibly, and with greater effectiveness to established and 
emerging trends in sexually transmitted diseases (STDs) through 
improved collection, reporting, analysis, visualization (i.e. mapping); 
and interpret STD surveillance data.
    This program addresses the ``Healthy People 2010'' focus area(s) 
of: HIV Infection, Immunization and Infectious Diseases, Public Health 
Infrastructure, and Sexually Transmitted Diseases.
    Measurable outcomes of the program will be in alignment with one or 
more of the following performance goals for the Coordinating Center for 
Infectious Diseases (CCID), National Center for HIV, STD, and TB 
Prevention (NCHSTP), Division of STD Prevention (DSTDP): (1) Reduce STD 
rates by providing chlamydia and gonorrhea screening, treatment, and 
partner treatment to 50 percent of women in publicly funded family 
planning and STD clinics nationally; (2) Reduce the incidence of 
primary and secondary syphilis; (3) Reduce the incidence of congenital 
syphilis; and (4) Strengthen the capacity nationwide to monitor the 
epidemic, develop and implement effective HIV prevention interventions, 
and evaluate prevention programs.
    This announcement is only for non-research activities supported by 
CDC/ATSDR. If research is proposed, the application will not be 
reviewed. For the definition of research, please see the CDC Web site 
at the following Internet address: https://www.cdc.gov/od/ads/
opspoll1.htm.
    Activities:
Required awardee activities for this program are as follows:
     Participate in conference calls and a CDC-organized 
meeting in the first quarter of the year one budget period to finalize 
a common protocol for enhanced gonorrhea surveillance and for at least 
one other emerging or existing STD area of concern. Types of data to be 
collected under the common protocol for enhanced gonorrhea 
surveillance, with relevance for other STDs may include: number and 
gender of sex partners; presence or absence of symptoms; sites of 
infection; STD/HIV infection history; level of education; internet 
usage; history of incarceration; performance drug use; and illicit 
substance use.
     Provide the human and technical resources necessary for 
collection, analysis, interpretation, and dissemination of enhanced 
gonorrhea surveillance data from one or more STD clinics; it is also 
desirable, but not required, that awardees conduct enhanced 
surveillance of gonorrhea in one or more surrounding counties.
     Awardees planning to conduct enhanced surveillance of GC 
in surrounding counties should conduct surveillance on a representative 
sample of patients with gonorrhea in the county in which the STD clinic 
is located.
     Collaborate with CDC and other awardees to identify other 
STDs and sexual health issues of interest (ex: LGV, resistant 
gonorrhea, resistant syphilis, increased illicit drug use), including 
those for which rapid implementation of surveillance and/or prevention 
activities are needed.
     Collaborate with CDC and other awardees to expeditiously 
develop common protocols to monitor and respond to STD-relevant trends.
     Provide the human and technical resources necessary to 
conduct enhanced surveillance for the collaboratively identified other 
STDs and sexual health issues.
     Work collaboratively with other awardees and CDC to 
standardize behavioral risk domains and achieve standardization of 
specific data elements.
     Collaborate to develop and implement common data elements 
and protocols.
     Plan to use or build upon currently existing electronic 
information systems for the collection, integration, analysis, and 
reporting of enhanced surveillance data.
     Electronically transmit data from STD surveillance 
activities to CDC on a monthly basis in a mutually agreed-upon format.
     Perform routine analyses of local STD surveillance data, 
including spatial or outbreak detection analyses; and evaluate the 
effectiveness of different methods of spatial or outbreak detection 
analysis in improving STD surveillance and program activities.
     Establish mechanisms by which STD enhanced and routine 
surveillance data are shared with stakeholders.
     Participate in annual collaboration meetings by reporting 
preliminary data and the status of ongoing activities, and working with 
other sites to develop or revise common enhanced surveillance activity 
protocols.
    In a cooperative agreement, CDC staff is substantially involved in 
the program activities, above and beyond routine grant monitoring. CDC 
Activities for this program are as follows:
     Draft common protocols for enhanced gonorrhea 
surveillance, in STD clinics and in counties, to be discussed and 
modified by awardees through conference calls and a meeting with 
awardees in the first quarter of the year one budget period.
     Analyze data from all awardees, and share results with 
stakeholders.
     Identify emerging trends in STDs and sexual health issues 
that merit further investigation by the STD surveillance network.
     Coordinate the development of new common surveillance and 
response protocols; standardization of data elements; and definition of 
data reporting formats through collaboration with awardees.
     Coordinate annual collaboration meetings to review and 
plan program activities.
     Collaborate directly in the publication and dissemination 
of project findings and experiences.
     Facilitate, where possible, and assist with the electronic 
transmission of data to CDC.

II. Award Information

    Type of Award: Cooperative Agreement. CDC involvement in this 
program is listed in the Activities Section above.
    Fiscal Year Funds: 2005.
    Approximate Total Funding: $400,000 (This amount is an estimate for 
the first 12-month budget period, and is subject to availability of 
funds.)
    Approximate Number of Awards: Five.
    Approximate Average Award: $80,000, if enhanced county-level 
surveillance is included; $60,000 for projects that don't include such 
an activity. (This amount is for the first 12-month budget period, and 
includes both direct and indirect costs.)

[[Page 36391]]

    Floor of Award Range: None.
    Ceiling of Award Range: $100,000 (This ceiling is for the first 12-
month budget period.)
    Anticipated Award Date: August 31, 2005.
    Budget Period Length: 12 months.
    Project Period Length: Three years.
    Throughout the project period, CDC's commitment to continuation of 
awards will be conditioned on the availability of funds, evidence of 
satisfactory progress by the recipient (as documented in required 
reports), and the determination that continued funding is in the best 
interest of the Federal Government.

III. Eligibility Information

III.1. Eligible Applicants

    Limited competition. Only the 65 state, county, city, and 
territorial health departments that are current recipients of 
Comprehensive STD Prevention Systems grants may apply for this program 
because participation in an STD surveillance network requires the 
participating entity to have the legal and programmatic capacity to 
collect and monitor health data, as well as the programmatic capacity 
to respond to emerging trends in disease and risk behaviors.

III.2. Cost Sharing or Matching

    Matching funds are not required for this program.

III.3. Other

    If you are requesting a funding amount greater than the ceiling of 
the award range, your application will be considered non-responsive and 
will not be entered into the review process. You will be notified that 
your application did not meet the submission requirements.
Special Requirements
    If your application is incomplete or non-responsive to the special 
requirements listed in this section, it will not be entered into the 
review process. You will be notified that your application did not meet 
submission requirements.
     Late applications will be considered non-responsive. See 
section ``IV.3. Submission Dates and Times'' for more information on 
deadlines.
     Letters of intent are requested.
     Awardees must ensure that enhanced gonorrhea surveillance 
activities occur in at least one STD clinic that diagnoses at least 150 
cases of gonorrhea per year; and, if the awardee plans to work in the 
surrounding county, the county in which the STD clinic is located 
receives reports of at least 100 cases of gonorrhea per year from other 
providers.
     Participation in Outcomes Assessment through Systems of 
Integrated Surveillance (OASIS) cooperative agreements 707, 
99000, or 02211 is useful, but not required, for 
meeting the requirements of this activity. If not a former OASIS 
participant, the applicant should demonstrate that they have 
significant experience conducting other types of enhanced STD 
surveillance, analyzing enhanced STD surveillance data, and 
disseminating findings to stakeholders.
     Note: Title 2 of the United States Code Section 1611 
states that an organization described in Section 501(c)(4) of the 
Internal Revenue Code that engages in lobbying activities is not 
eligible to receive Federal funds constituting an award, grant, or 
loan.

IV. Application and Submission Information

IV.1. Address To Request Application Package

    To apply for this funding opportunity use application form CDC 
5161-1.
    CDC strongly encourages you to submit your application 
electronically by utilizing the forms and instructions posted for this 
announcement at https://www.grants.gov.
    Application forms and instructions are available on the CDC Web 
site, at the following Internet address: https://www.cdc.gov/od/pgo/
forminfo.htm.
    If you do not have access to the Internet, or if you have 
difficulty accessing the forms on-line, you may contact the CDC 
Procurement and Grants Office Technical Information Management Section 
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to 
you.

IV.2. Content and Form of Submission

    Letter of Intent (LOI): Your LOI must be written in the following 
format:
     Maximum number of pages: 1.
     Font size: 12-point unreduced.
     Single spaced.
     Paper size: 8.5 by 11 inches.
     Page margin size: One inch.
     Printed only on one side of page.
     Written in plain language, avoid jargon.
    Your LOI must contain the following information:
     Your intent to apply for this application.
     The name of the project coordinator(s).
     The name of any proposed collaborator(s).
     The name, address, telephone, e-mail, and fax number of 
the applicant's primary point of contact for writing and submitting the 
application.
    Application: You must submit a project narrative with your 
application forms. The narrative must be submitted in the following 
format:
     Maximum number of pages: 20. If your narrative exceeds the 
page limit, only the first pages which are within the page limit will 
be reviewed.
     Font size: 12 point unreduced.
     Double spaced.
     Paper size: 8.5 by 11 inches.
     Page margin size: One inch.
     Printed only on one side of page.
     Held together only by rubber bands or metal clips; not 
bound in any other way.
     The funding opportunity title and number must appear on 
the first page.
    Your narrative should address activities to be conducted over the 
entire project period, and must include the following items in the 
order listed: Background/Need, Objectives, Plan, Method, Experience, 
Timeline, Capacity, Evaluation Plans, Sustainability, and Line-Item 
Budget with Justifications. More detailed descriptions of these items 
are described in section V.1. ``Criteria'' of this announcement.
    Additional information may be included in the application 
appendices. The appendices will not be counted toward the narrative 
page limit. This additional information includes:
     Curriculum Vitas.
     Organizational Charts.
     Letters of Support.
    You are required to have a Dun and Bradstreet Data Universal 
Numbering System (DUNS) number to apply for a grant or cooperative 
agreement from the Federal Government. The DUNS number is a nine-digit 
identification number, which uniquely identifies business entities. 
Obtaining a DUNS number is easy and there is no charge. To obtain a 
DUNS number, access https://www.dunandbradstreet.com or call 1-866-705-
5711.
    For more information, see the CDC Web site at: https://www.cdc.gov/
od/pgo/funding/pubcommt.htm. If your application form does not have a 
DUNS number field, please write your DUNS number at the top of the 
first page of your application, and/or include your DUNS number in your 
application cover letter.
    Additional requirements that may require you to submit additional 
documentation with your application are listed in section ``VI.2. 
Administrative and National Policy Requirements.''

IV.3. Submission Dates and Times

    LOI Deadline Date: July 8, 2005.

[[Page 36392]]

    CDC requests that you submit a LOI if you intend to apply for this 
program. Although the LOI is not required, not binding, and does not 
enter into review of your subsequent application, the LOI will be used 
to gauge the level of interest in this program, and allow CDC to plan 
the application review.
    Application Deadline Date: July 25, 2005.
    Explanation of Deadlines: LOIs and Applications must be received in 
the CDC Procurement and Grants Office by 4 p.m. eastern time on the 
deadline date.
    You may submit your application electronically at https://
www.grants.gov. Applications completed online through Grants.gov are 
considered formally submitted when the applicant organization's 
Authorizing Official electronically submits the application to https://
www.grants.gov. Electronic application will be considered as having met 
the deadline if the application has been submitted electronically by 
the applicant organization's Authorizing Official to Grants.gov on or 
before the deadline date and time.
    If you submit your application electronically with Grants.gov, your 
application will be electronically time/date stamped, which will serve 
as receipt of submission. You will receive an e-mail notice of receipt 
when CDC receives the application.
    If you submit your LOI or application by the United States Postal 
Service or commercial delivery service, you must ensure that the 
carrier will be able to guarantee delivery by the closing date and 
time. If CDC receives your submission after closing due to: (1) Carrier 
error, when the carrier accepted the package with a guarantee for 
delivery by the closing date and time; or (2) significant weather 
delays or natural disasters, you will be given the opportunity to 
submit documentation of the carrier's guarantee. If the documentation 
verifies a carrier problem, CDC will consider the submission as having 
been received by the deadline.
    If you submit a hard copy application, CDC will not notify you upon 
receipt of your submission. If you have a question about the receipt of 
your LOI or application, first contact your courier. If you still have 
a question, contact the PGO-TIM staff at: 770-488-2700. Before calling, 
please wait two to three days after the submission deadline. This will 
allow time for submissions to be processed and logged.
    This announcement is the definitive guide on LOI and application 
content, submission address, and deadline. It supersedes information 
provided in the application instructions. If your submission does not 
meet the deadline above, it will not be eligible for review, and will 
be discarded. You will be notified that you did not meet the submission 
requirements.

IV.4. Intergovernmental Review of Applications

    Your application is subject to Intergovernmental Review of Federal 
Programs, as governed by Executive Order (EO) 12372. This order sets up 
a system for State and local governmental review of proposed federal 
assistance applications. You should contact your state single point of 
contact (SPOC) as early as possible to alert the SPOC to prospective 
applications, and to receive instructions on your state's process. 
Click on the following link to get the current SPOC list: https://
www.whitehouse.gov/omb/grants/spoc.html.

IV.5. Funding Restrictions

    Restrictions, which must be taken into account while writing your 
budget, are as follows:
     Funds may not be used for research.
     Reimbursement of pre-award costs is not allowed.
     Funds may not be used for construction.
    If you are requesting indirect costs in your budget, you must 
include a copy of your indirect cost rate agreement. If your indirect 
cost rate is a provisional rate, the agreement should be less than 12 
months of age.
    Guidance for completing your budget can be found on the CDC Web 
site, at the following Internet address: https://www.cdc.gov/od/pgo/
funding/budgetguide.htm.

IV.6. Other Submission Requirements

    LOI Submission Address: Submit your LOI by express mail, delivery 
service, fax, or e-mail to: Lori Newman, MD, Project Officer, CDC/
NCHSTP/DSTDP, Mailstop E-02, 1600 Clifton Road, Atlanta, GA 30333, 
(404) 639-6183, (404) 639-8610 (fax); len4@cdc.gov.
    Application Submission Address: CDC strongly encourages applicants 
to submit electronically at: https://www.grants.gov. You will be able to 
download a copy of the application package from https://www.grants.gov, 
complete it offline, and then upload and submit the application via the 
Grants.gov site. E-mail submissions will not be accepted. If you are 
having technical difficulties in Grants.gov, they can be reached by e-
mail at http:www.support@grants.gov">//www.support@grants.gov or by phone at 1-800-518-4726 (1-
800-GRANTS). The Customer Support Center is open from 7 a.m. to 9 p.m. 
eastern time, Monday through Friday.
    CDC recommends that you submit your application to Grants.gov early 
enough to resolve any unanticipated difficulties prior to the deadline. 
You may also submit a back-up paper submission of your application. Any 
such paper submission must be received in accordance with the 
requirements for timely submission detailed in Section IV.3. of the 
grant announcement. The paper submission must be clearly marked: 
``Back-Up for Electronic Submission.''
    The paper submission must conform to all requirements for non-
electronic submissions. If both electronic and back-up paper 
submissions are received by the deadline, the electronic version will 
be considered the official submission.
    It is strongly recommended that you submit your grant application 
using Microsoft Office products (e.g., Microsoft Word, Microsoft Excel, 
etc.). If you do not have access to Microsoft Office products, you may 
submit a PDF file. Directions for creating PDF files can be found on 
the Grants.gov Web site. Use of file formats other than Microsoft 
Office or PDF may result in your file being unreadable by our staff.

Or:

    Submit the original and two hard copies of your application by mail 
or express delivery service to: Technical Information Management-PA 
AA055, CDC Procurement and Grants Office, 2920 Brandywine Road, 
Atlanta, GA 30341.

V. Application Review Information

V.1. Criteria

    Applicants are required to provide measures of effectiveness that 
will demonstrate the accomplishment of the various identified 
objectives of the cooperative agreement. Measures of effectiveness must 
relate to the performance goals stated in the ``Purpose'' section of 
this announcement. Measures must be objective and quantitative, and 
must measure the intended outcome. These measures of effectiveness must 
be submitted with the application and will be an element of evaluation. 
Your application will be evaluated against the following criteria:
     Methods: (25 points total)
    (a) To what extent does the applicant demonstrate that methods for 
STD clinic-based surveillance, information management, and disease 
investigation and response are flexible and could be adapted for other 
types of enhanced STD and behavioral surveillance in such

[[Page 36393]]

settings? Has the applicant included letters from collaborating clinics 
and county health departments that demonstrate their support? If the 
application is from a county or a city, does the application include a 
letter of support from the state? (15 points)
    (b) The applicant should clearly indicate if their plans include 
enhanced surveillance of gonorrhea from the surrounding county. If 
included, what is the extent to which methods are sound and analyses 
will describe a representative sample of persons reported to have 
gonorrhea in the county? Has the applicant included letters from 
collaborating facilities and county health departments that demonstrate 
their support? (10 points)
     Capacity: (20 points total)
    (a) Is the proposed staff capacity sufficient to conduct enhanced 
data collection, entry, cleaning, analysis, evaluation, and 
dissemination? Does the project staff have the appropriate background, 
experience, and time to perform the proposed work? (10 points)
    (b) Does the applicant have existing information management systems 
with the capacity to merge or integrate electronic data from providers, 
laboratories, or other data sources? Does the applicant have a database 
that can be queried, can generate line listed clinic visit/patient 
data, and can easily be modified to incorporate new data elements? (10 
points)
     Objectives/Plan: (15 points total)
    What is the quality of the proposed plan to participate in an 
enhanced surveillance network to collect enhanced gonorrhea data, as 
well as data on other emerging or existing STD issues? Consider clarity 
of objectives and soundness of the applicant's approach. The applicant 
should demonstrate an understanding of the potential utility of 
enhanced STD surveillance at both the local and national level. The 
applicant should indicate a willingness to collaborate with other 
grantees funded for this project, and adhere to a common standard 
protocol.
     Experience: (15 points total)
    Did the applicant participate in previous Outcomes Assessment 
through Systems of Integrated Surveillance (OASIS) cooperative 
agreements 707, 99000, or 02211, and 
demonstrate their ability to successfully conduct enhanced gonorrhea 
surveillance and work collaboratively with other sites? OR Does the 
applicant demonstrate that they have significant experience conducting 
other types of enhanced STD surveillance, analyzing enhanced STD 
surveillance data, and disseminating findings to stakeholders?
     Background/Need: (10 points total)
    How well has the applicant described the target population, and 
justified the need for this program within the target population? Is 
the gonorrhea morbidity in the target population sufficient to merit 
enhanced surveillance and subsequent interventions? To what extent does 
the STD clinic have a large and varied clientele (with regard to 
gender, race, ethnicity, and sexual orientation) who experience a range 
of STDs, and a professional staff with the ability to recognize, 
correctly diagnose, and treat emerging STDs and sexual issues? (Note: 
It is required that the STD clinic see a minimum average of 150 
patients of gonorrhea per year.) What is the STD burden in the 
designated county? (Note: For awardees planning enhanced surveillance 
in the county, the county must have at least an additional 100 reported 
cases of gonorrhea a year reported from other providers.)
     Evaluation Plans: (5 points total)
    Has the applicant set forth clear performance goals? Has the 
applicant outlined outcome measures that are objective, quantitative, 
and adequately measure the intended outcome? To what extent does the 
applicant demonstrate their ability and intent to disseminate and 
translate the data into programmatic action?
     Timeline: (5 points total)
    Has the applicant proposed an achievable timeline? Has the 
applicant documented their ability to implement the proposed plan for 
enhanced gonorrhea surveillance within the first year of the project 
period?
     Sustainability: (5 points total)
    To what extent has the applicant demonstrated that activities could 
be institutionalized as ongoing surveillance activities?
     Budget and Justification: (Reviewed, but not scored.)
    Is the budget reasonable, clearly justified, and consistent with 
the intended use of funds?

V.2. Review and Selection Process

    Applications will be reviewed for completeness by the Procurement 
and Grants Office (PGO) staff, and for responsiveness by NCHSTP/DSTDP. 
Incomplete applications and applications that are non-responsive to the 
eligibility criteria will not advance through the review process. 
Applicants will be notified that their application did not meet 
submission requirements.
    An objective review panel of CDC employees will evaluate complete 
and responsive applications according to the criteria listed in the 
``V.1. Criteria'' section above. All members of the objective review 
panel will come from outside of the funding division of NCHSTP.
    In addition, the following factors may affect the funding decision:
     The need for geographic diversity may affect applicant 
selection.
     Applicant selection may be affected by the importance of 
covering high gonorrhea morbidity areas.
     Applicant selection may be affected by the importance of 
including populations that broadly represent patients with gonorrhea by 
gender, race, ethnicity, and sexual orientation.
    CDC will provide justification for any decision to fund out of rank 
order.

V.3. Anticipated Announcement and Award Dates

    August 31, 2005.

VI. Award Administration Information

VI.1. Award Notices

    Successful applicants will receive a Notice of Award (NoA) from the 
CDC Procurement and Grants Office. The NoA shall be the only binding, 
authorizing document between the recipient and CDC. The NoA will be 
signed by an authorized Grants Management Officer, and mailed to the 
recipient fiscal officer identified in the application. Unsuccessful 
applicants will receive notification of the results of the application 
review by mail.

VI.2. Administrative and National Policy Requirements

45 CFR part 74 and part 92
    For more information on the Code of Federal Regulations, see the 
National Archives and Records Administration at the following Internet 
address: https://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
    The following additional requirements apply to this project:

 AR-4 HIV/AIDS Confidentiality Provisions.
 AR-6 Patient Care.
 AR-7 Executive Order 12374 Review.
 AR-9 Paperwork Reduction Act Requirements.
 AR-10 Smoke-Free Workplace Requirements.
 AR-11 Healthy People 2010.

    Additional information on these requirements can be found on the 
CDC Web site at the following Internet address: https://www.cdc.gov/od/
pgo/funding/ARs.htm.
    An additional Certification form from the PHS 5161-1 application 
needs to be included in your Grants.gov electronic submission only. 
Refer to https://www.cdc.gov/od/pgo/funding/

[[Page 36394]]

PHS5161-1Certificates.pdf. Once the form is filled out, attach it to 
your Grants.gov submission as Other Attachment Forms.

VI.3. Reporting Requirements

    You must provide CDC with an original, plus two hard copies of the 
following reports:
    1. Interim progress report, due by June 30th of each funding year. 
The progress report will serve as your non-competing continuation 
application, and must contain the following elements:
    a. Current Budget Period Activities Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.
    d. Budget.
    e. Measures of Effectiveness.
    f. Additional Requested Information.
    2. Financial status report and annual progress report, due by 
December 30 of each funding year.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    These reports must be mailed to the Grants Management or Contract 
Specialist listed in the ``Agency Contacts'' section of this 
announcement.

VII. Agency Contacts

    We encourage inquiries concerning this announcement. For general 
questions, contact: Technical Information Management Section, CDC 
Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341; 
telephone: 770-488-2700.
    For program technical assistance, contact: Lori Newman, MD, Project 
Officer, Mailstop E-02, 1600 Clifton Road, Atlanta, GA 30333, 
telephone: 404-639-6183; e-mail: len4@cdc.gov.
    For financial, grants management, or budget assistance, contact: 
Gladys Gissentanna, Grants Management Specialist, CDC Procurement and 
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, telephone: 770-
488-2753; e-mail: gcg4@cdc.gov.

VIII. Other Information

    This and other CDC funding opportunity announcements can be found 
on the CDC Web site, Internet address: https://www.cdc.gov. Click on 
``Funding'' then ``Grants and Cooperative Agreements.''

    Dated: June 17, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 05-12410 Filed 6-22-05; 8:45 am]
BILLING CODE 4163-18-P